Mutations conferring differential treatment response in breast cancer

Poor prognosis primary breast cancer patients usually receive cytotoxic chemotherapy as a component of treatment, but despite this aggressive therapy recurrences remain common. Improved understanding of chemoresistance pathways would allow better stratification of chemotherapy using predictive markers, and may allow therapeutic inhibition of resistance mechanisms in order to chemosensitise tumours. We aimed to identify molecular pathways that define chemoresponse using the novel approach of examining the selection exerted by neoadjuvant chemotherapy on sub-clonal somatic mutational profiles of cancer cells.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001004984	Fastq files resulting from whole exome sequencing of trios of samples from 6 breast cancer patients: normal breast, pre-NAC biopsy and post-NAC surgical resection.	Illumina HiSeq 3000	17

Publications	Citations
Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants. Al Amri WS, Baxter DE, Hanby AM, Stead LF, Verghese ET, Thorne JL, Hughes TA. Breast Cancer Res Treat 183: 2020 607-616	11